Based on these assessments tumors are divided into ER + , HER2 + with or without ER + , and triple negative breast cancer (TNBC) subgroups, and this categorization has been used to identify treatment options [1]. The gene discussed is ESR1; the disease is triple-negative breast carcinoma.